Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved Test,who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) .Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).
FDA,2022.12
Mechanism of Action of AdagrasibSpecific alterations in the KRAS gene produce an···【more】
Release date:2026-04-22Recommended:29
What is adagrasib?Adagrasib is an oral prescription targeted therapy designed fo···【more】
Release date:2026-04-21Recommended:29
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Release date:2026-01-05Recommended:53